Apmonia is focused on developing new therapies for cancer patients via its technology platform, which leverages recent advances in computational protein and peptide engineering, as well as cutting-edge screening and validation technologies.

In September 2023, the French company agreed terms for a licensing and co-development program with SATT Nord. Apmonia received $2.7 million in funding last year from public sector investment bank Bpifrance, supporting its work targeting elements of the extracellular matrix.